A phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb’s Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer met the primary endpoint of overall survival compared to chemo alone for up to four cycles followed by optional maintenance therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
